These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 27887596)

  • 21. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial.
    Solanki BB; Juergens C; Chopada MB; Supe P; Sundaraiyer V; Le Dren-Narayanin N; Cutler MW; Gruber WC; Scott DA; Schmoele-Thoma B
    Hum Vaccin Immunother; 2017 Sep; 13(9):2065-2071. PubMed ID: 28881165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomised revaccination with pneumococcal polysaccharide or conjugate vaccine in asplenic children previously vaccinated with polysaccharide vaccine.
    Smets F; Bourgois A; Vermylen C; Brichard B; Slacmuylders P; Leyman S; Sokal E
    Vaccine; 2007 Jul; 25(29):5278-82. PubMed ID: 17576024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccine.
    Bryant KA; Frenck R; Gurtman A; Rubino J; Treanor J; Thompson A; Jones TR; Sundaraiyer V; Baxter LM; Gruber WC; Emini EA; Scott DA; Schmoele-Thoma B
    Vaccine; 2015 Oct; 33(43):5854-5860. PubMed ID: 26362099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeat pneumococcal polysaccharide vaccine in Indigenous Australian adults is associated with decreased immune responsiveness.
    Moberley S; Licciardi PV; Balloch A; Andrews R; Leach AJ; Kirkwood M; Binks P; Mulholland K; Carapetis J; Tang MLK; Skull S
    Vaccine; 2017 May; 35(22):2908-2915. PubMed ID: 28455171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study.
    Zaman K; Zaman SF; Zaman F; Aziz A; Faisal SB; Traskine M; Habib MA; Ruiz-Guiñazú J; Borys D
    Vaccine; 2018 Jan; 36(5):698-706. PubMed ID: 29277353
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants.
    Knuf M; Pankow-Culot H; Grunert D; Rapp M; Panzer F; Köllges R; Fanic A; Habib A; Borys D; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2012 Jan; 31(1):e31-6. PubMed ID: 21909049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-Effectiveness Analysis of 23-Valent Pneumococcal Polysaccharide Vaccine Program for the Elderly Aged 60 Years or Older in Shanghai, China.
    Sun X; Tang Y; Ma X; Guo X; Huang Z; Ren J; Qiu J; Jiang H; Lu Y
    Front Public Health; 2021; 9():647725. PubMed ID: 34109145
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada.
    Vanderkooi OG; Scheifele DW; Girgenti D; Halperin SA; Patterson SD; Gruber WC; Emini EA; Scott DA; Kellner JD;
    Pediatr Infect Dis J; 2012 Jan; 31(1):72-7. PubMed ID: 21960186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants.
    Prymula R; Szenborn L; Silfverdal SA; Wysocki J; Albrecht P; Traskine M; Gardev A; Song Y; Borys D
    Vaccine; 2017 Aug; 35(35 Pt B):4603-4611. PubMed ID: 28729019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long term-care residents in Brazil.
    Brandão AP; de Oliveira TC; de Cunto Brandileone MC; Gonçalves JE; Yara TI; Simonsen V
    Vaccine; 2004 Dec; 23(6):762-8. PubMed ID: 15542200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults.
    McFetridge R; Meulen AS; Folkerth SD; Hoekstra JA; Dallas M; Hoover PA; Marchese RD; Zacholski DM; Watson WJ; Stek JE; Hartzel JS; Musey LK
    Vaccine; 2015 Jun; 33(24):2793-9. PubMed ID: 25913828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between asthma status and antibody response pattern to 23-valent pneumococcal vaccination.
    Sheen YH; Kizilbash S; Ryoo E; Wi CI; Park M; Abraham RS; Ryu E; Divekar R; Juhn Y
    J Asthma; 2020 Apr; 57(4):381-390. PubMed ID: 30784333
    [No Abstract]   [Full Text] [Related]  

  • 34. The effectiveness of revaccination with pneumococcal polysaccharide vaccine for preventing pneumococcal disease in older adults in England: A population-based cohort study.
    Doherty K; Bonnett L; Agbla SC; Beveridge NER; Decraene V; Fleming KM; Hungerford D; French N
    Vaccine; 2024 Sep; 42(22):126002. PubMed ID: 38796329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Revaccination with pneumococcal vaccine of elderly persons 6 years after primary vaccination.
    Mufson MA; Hughey DF; Turner CE; Schiffman G
    Vaccine; 1991 Jun; 9(6):403-7. PubMed ID: 1887670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis.
    Garrido HMG; Schnyder JL; Tanck MWT; Vollaard A; Spijker R; Grobusch MP; Goorhuis A
    EClinicalMedicine; 2020 Dec; 29-30():100576. PubMed ID: 33294820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pneumococcal vaccination and revaccination of older adults.
    Artz AS; Ershler WB; Longo DL
    Clin Microbiol Rev; 2003 Apr; 16(2):308-18. PubMed ID: 12692100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines.
    Hilleman MR; Carlson AJ; McLean AA; Vella PP; Weibel RE; Woodhour AF
    Rev Infect Dis; 1981; 3 Suppl():S31-42. PubMed ID: 7025159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia.
    Törling J; Hedlund J; Konradsen HB; Ortqvist A
    Vaccine; 2003 Dec; 22(1):96-103. PubMed ID: 14604576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease.
    Reinert P; Benkerrou M; de Montalembert M; Lesprit E; Abadie I; Bernaudin F; Doit C; Bingen E; Tetelboum R; Bonnet E
    Pediatr Infect Dis J; 2007 Dec; 26(12):1105-9. PubMed ID: 18043446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.